Answers are grounded in this paper and cite their sources.
Translational study demonstrates repertoire-wide clonotype-resolved immune response monitoring in human lung cancer, suggesting new avenues for personalized immunotherapy design.
T cell responses across the TCR repertoire are central to immunotherapies. However, current methods cannot simultaneously achieve broad antigen coverage, high TCR resolution, and high throughput, and therefore provide only a partial view of T cell responses. Here, we introduce the T-SCOPE strategy for repertoire-wide, clonotype-resolved T cell response monitoring. By directly linking response potency with TCR sequences across the entire TCR repertoire, T-SCOPE facilitates the unbiased identification and assessment of antigen response potency for individual TCRs. T-SCOPE integrates single-cell RNA sequencing, paired single-cell TCR sequencing, and cell-surface DNA barcoding to simultaneously profile gene expression, labeling intensity, sample identity, and TCR sequences at single-cell resolution. This platform enables response potency ranking of antigen-specific TCRs and monitors the T cell response landscape to global tumor antigens in human clinical samples. Altogether, T-SCOPE provides a functional platform for monitoring dynamic antigen responses in both physiological and clinical settings.
No takes yet. Share an insight, caveat, or question.
欧阳时安(Shian Ouyang) (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: